Acadia Pharmaceuticals

ACAD · Nasdaq · United States

Share price · ACAD

$17.83-12.35 (-40.92%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.9M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ACAD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026+10.8%
  2. 9 Nov 2026-22.3%
  3. 25 Sep 2026-6.8%
  4. 24 Sep 2026-12.8%
  5. 21 Sep 2026-3.3%
  6. 18 Aug 2026+4.0%

    Nothing announced by ACAD that day or the session before.

  7. 5 Aug 2026+6.1%
  8. 26 Jun 2026+6.7%
  9. 7 May 2026+5.0%
  10. 2 Mar 2026-7.1%

    Nothing announced by ACAD that day or the session before.

Share of unusual movement by asset

For each asset, the share of ACAD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Trofinetide
events and moves
4shown from 8 days
Remlifanserin
events and moves
3shown from 8 days
Pimavanserin (Nuplazid)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—23%
Other company news (earnings, financing, releases naming no asset)—19%
Sessions with no dated event—58%

Assets

(4 total)
4Total Assets
2Approved
1Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Pimavanserin(Nuplazid)
Approved
5-HT2A/2C receptor · Serotonin 5-HT2A receptor (antagonist / inverse agonist)Small molecule
Parkinson's Disease Psychosis
Approved
—Peptide
Rett Syndrome
Phase 3
Serotonin 5-HT2A receptor (antagonist / inverse agonist)Small molecule
Alzheimer's DiseaseAlzheimer's Disease Psychosis
Phase 2
NMDA receptorSmall molecule
Major Depressive Disorder

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
August 2027 (1)
ACP-211Phase 2Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
Est. primary completion 2027-08 · NCT07284667 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
RemlifanserinPhase 2/3Alzheimer's Disease Psychosis
Est. primary completion 2028-01 · NCT06159673 · CT.gov ↗
What to watch
February 2028 (1)
RemlifanserinPhase 2Lewy Body Dementia Psychosis
Est. primary completion 2028-02 · NCT07029581 · CT.gov ↗
What to watch
2029 (2)
February 2029 (1)
RemlifanserinPhase 3Lewy Body Dementia Psychosis
Est. primary completion 2029-02 · NCT07095465 · CT.gov ↗
What to watch
April 2029 (1)
RemlifanserinPhase 3Alzheimer's Disease Psychosis
Est. primary completion 2029-04 · NCT06194799 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 September 2026Topline resultRemlifanserinPhase 2 RADIANT topline results
Acadia Pharmaceuticals Inc. · Source ↗
October 2024Topline resultPimavanserinPediatric Phase 2 in autism-related irritability did not meet its primary endpoint
March 2024Topline resultPimavanserinPhase 3 ADVANCE-2 in negative symptoms of schizophrenia did not meet its primary endpoint

Financial reports

Quarterly & interim (19)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$342M$76M$322M+ $654M short-term inv.—$12M operating cash flowreport ↗
View 18 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$308M$82M$385M+ $571M short-term inv.—$101M operating cash flowreport ↗
2026-Q1$268M$77M$282M+ $569M short-term inv.—$34M operating cash flowreport ↗
2025-Q3$279M$88M$258M+ $589M short-term inv.—$74M operating cash flowreport ↗
2025-Q2$265M$78M$254M+ $508M short-term inv.—$64M operating cash flowreport ↗
2025-Q1$244M$78M$218M+ $464M short-term inv.—$20M operating cash flowreport ↗
2024-Q3$250M$67M$155M+ $410M short-term inv.—$63M operating cash flowreport ↗
2024-Q2$242M$76M$177M+ $324M short-term inv.—$25M operating cash flowreport ↗
2024-Q1$206M$60M$205M+ $266M short-term inv.—$29M operating cash flowreport ↗
2023-Q4——$189M+ $250M short-term inv.—$85M operating cash flowreport ↗
2023-Q3$212M$157M$98M+ $248M short-term inv.$65M-$59M operating cash flowreport ↗
2023-Q2$165M$59M$108M+ $267M short-term inv.—$8.2M operating cash flowreport ↗
2023-Q1$118M$69M$291M+ $112M short-term inv.$43M-$18M operating cash flowreport ↗
2022-Q4——$115M+ $302M short-term inv.$42M-$24M operating cash flowreport ↗
2022-Q3$131M$81M$155M+ $282M short-term inv.$27M-$0.7M operating cash flowreport ↗
2022-Q2$135M$76M$140M+ $297M short-term inv.$34M-$13M operating cash flowreport ↗
2022-Q1$115M$129M$205M+ $241M short-term inv.$113M-$76M operating cash flowreport ↗
2021-Q4——$147M+ $373M short-term inv.$43M-$23M operating cash flowreport ↗
2021-Q3$132M$59M$95M+ $446M short-term inv.$14M-$17M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.1B$329M$178M+ $642M short-term inv.—$110M operating cash flowreport ↗

Acadia Pharmaceuticals reported full-year 2025 revenue of $1,071.51M, up 11.9% YoY, with research and development spend of $328.8M, up 8.4% YoY. Cash and equivalents stood at $177.7M, and the company recorded net income of $391M. The company also reported non-GAAP adjusted total revenues of $1.08B for the year, up 14% YoY, reflecting an adjustment for a one-time Inflation Reduction Act rebate accrual charge.

For 2026, Acadia guided total revenues of $1.22 to $1.28B, NUPLAZID net sales of $760 to $790M, DAYBUE net sales of $460 to $490M, R&D expense of $385 to $410M, and SG&A expense of $660 to $700M. The company expects top-line results from the remlifanserin Phase 2 RADIANT study in Alzheimer’s disease psychosis between August and October 2026, and has shipped initial DAYBUE STIX product to patients ahead of a broader launch planned for early Q2 2026. Acadia also completed a planned 30% expansion of its NUPLAZID customer-facing teams.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$958M$303M$320M+ $436M short-term inv.—$158M operating cash flowreport ↗
2023-FY$726M$352M$189M+ $250M short-term inv.$15M$17M operating cash flowreport ↗
2022-FY$517M$362M$115M+ $302M short-term inv.$54M-$114M operating cash flowreport ↗
2021-FY$484M$239M$147M+ $373M short-term inv.$42M-$126M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 22 sales ($2.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-30Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICEROpen-market sale3,321$20.88$69KForm 4
2026-10-15Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICERAward / grant6,815——Form 4
2026-08-06Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICEROption exercise14,292$17.84$255KForm 4
2026-08-06Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICEROpen-market sale5,000$29.00$145KForm 4
2026-08-06Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICEROpen-market sale9,292$29.34$273KForm 4
2026-08-06Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICEROption exercise (derivative)14,292——Form 4
2026-08-05Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICEROption exercise5,849$17.84$104KForm 4
2026-08-05Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICEROpen-market sale5,849$29.00$170KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 338 reporting institutions held 165.0M shares ($3.6B, 95.5% of shares outstanding).

#InstitutionSharesValue
1BAKER BROS. ADVISORS LP42,896,690$954.9M
2BlackRock, Inc.21,550,921$479.7M
3VANGUARD PORTFOLIO MANAGEMENT LLC8,671,645$193.0M
4STATE STREET CORP8,332,771$185.5M
5RTW INVESTMENTS, LP7,144,524$159.0M
6VANGUARD CAPITAL MANAGEMENT LLC5,661,400$126.0M
7GEODE CAPITAL MANAGEMENT, LLC3,464,689$77.1M
8FIRST TRUST ADVISORS LP3,343,868$74.4M
9DIMENSIONAL FUND ADVISORS LP3,155,160$70.2M
10Palo Alto Investors LP2,872,695$63.9M
11Point72 Asset Management, L.P.2,577,916$57.4M
12BRAIDWELL LP2,471,199$55.0M
13Pictet Asset Management Holding SA2,026,044$44.7M
14RENAISSANCE TECHNOLOGIES LLC1,724,196$38.4M
15ARROWSTREET CAPITAL, LIMITED PARTNERSHIP1,569,491$34.9M